Nektar outlines $1B market opportunity for REZPEG in alopecia areata as Phase III plans advance

Get the latest Nektar Therapeutics Q3 2025 earnings call insights—financial updates, REZPEG trial milestones, and market opportunities.
The Lancet

A viral clonality evenness score to predict progression to adult T-cell leukaemia in ...

The implementation of VCE scoring in clinical practice could inform early pre-emptive therapeutic interventions, exclusively ...

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025

The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green CNS(Vafidemstat) Received feedback ...

SES AI: AI Chemistry And Revenue Inflection Of A High-Growth Story

Discover why SES AI Corporation's innovative battery tech, soaring revenue, and strong AI platform signal 83% upside ...